TURBO UNLIMITED SHORT- OPTIONSSCHEIN OHNE STOPP-LOSS-LEVEL - VERTEX PHARMACEUTICALS TURBO UNLIMITED SHORT- OPTIONSSCHEIN OHNE STOPP-LOSS-LEVEL - VERTEX PHARMACEUTICALS Share Price
Certificat
DE000SU52N14
| Market Closed - Boerse Frankfurt Warrants 20:45:28 26/06/2024 BST | ||
| 28.18 EUR | +0.04% |
|
| Current month | -4.25% | ||
| 1 month | -3.79% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 26/06/24 | 28.19 | +0.07% |
| 25/06/24 | 28.17 | +1.19% |
| 24/06/24 | 27.84 | -2.18% |
| 21/06/24 | 28.46 | +0.11% |
| 20/06/24 | 28.43 | -1.08% |
Real-time Boerse Frankfurt Warrants
Last update June 26, 2024 at 08:45 pm
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | 
Société Générale
|
| WKN | SU52N1 |
| ISIN | DE000SU52N14 |
| Date issued | 20/12/2023 |
| Strike | 772.5 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 33.64 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 35.84 € |
|---|---|
| Lowest since issue | 26.31 € |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
474
USD
Average target price
465.5
USD
Spread / Average Target
-1.79%
- Stock Market
- Certificates
- Certificat
